Nirvana Life Sciences Inc.
NIRV
CNSX
| 10/31/2024 | 07/31/2024 | 04/30/2024 | 01/31/2024 | 10/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -54.48% | -49.84% | -42.56% | -28.29% | -19.09% |
| Depreciation & Amortization | -60.18% | -73.58% | -80.41% | -63.05% | -52.39% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -55.06% | -50.23% | -40.02% | -27.55% | -27.17% |
| Operating Income | 55.06% | 50.23% | 40.02% | 27.55% | 27.17% |
| Income Before Tax | 68.97% | 64.38% | 41.93% | 79.99% | 76.24% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 68.97% | 64.38% | 41.93% | 79.99% | 76.24% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -77.14% | -72.73% | -60.00% | -26.47% | 66.67% |
| Net Income | 68.94% | 64.36% | 41.89% | 80.03% | 76.30% |
| EBIT | 55.06% | 50.23% | 40.02% | 27.55% | 27.17% |
| EBITDA | 52.64% | 49.39% | 40.05% | 27.92% | 28.86% |
| EPS Basic | 76.53% | 73.86% | 56.71% | 83.95% | 80.57% |
| Normalized Basic EPS | 81.58% | 78.16% | 56.07% | 87.41% | 83.97% |
| EPS Diluted | 76.53% | 73.86% | 56.71% | 83.95% | 80.57% |
| Normalized Diluted EPS | 81.58% | 78.16% | 56.07% | 87.41% | 83.97% |
| Average Basic Shares Outstanding | 21.92% | 33.93% | 37.61% | 31.20% | 18.02% |
| Average Diluted Shares Outstanding | 21.92% | 33.93% | 37.61% | 31.20% | 18.02% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
